Dernières nouvelles pour Alzamend Neuro (NASDAQ:ALZN) Stock

Alzamend Neuro

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Alzamend Neuro Inc

WIIM

DNMR

Danimer Scientific shares are trading lower. The company reported Q3 financial results.

News

Events

Exclusives

$BTC

$ETH

GOOG

GOOGL

Google's Richard Widmann Says Stripe's Acquisition Of Bridge Has 'Opened People's Eyes' On New Ways Of Moving Value Across The Chain

Richard Widmann, Head Of Strategy, Web3 For Google Cloud, Says Looking At Web3 'We're not just moving information, we're moving value'

The European Union's Markets in Crypto-Assets (MiCA) regulation is set for full implementation by December 2024, placing pressure on crypto exchanges and asset providers to meet stringent new standards. 
Ahead of her appearance at the upcoming <a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets event</a>, Sandra Ro, CEO of Global Blockchain Business Council (GBBC), discussed the challenges facing European market players as they prepare for MiCA's requirements.
Reflecting on earlier compliance deadlines, Ro noted confusion led many exchanges to delist certain assets: "As we saw in the June 30 MiCA deadline for fiat-backed stablecoin compliance, there was confusion in the market, and most crypto exchanges decided to delist certain ‘non-compliant' stablecoins."
<h1 class="wp-block-heading">Travel Rule Compliance and Industry Uncertainty</h1>
With MiCA's travel rule set to take effect in December 2024, Ro pointed to ongoing concerns about how it will apply to crypto asset service providers (CASPs) across Europe. The rule will require CASPs to track information on crypto transactions for transparency. 
<figure class="wp-block-image size-full"><a href="https://benzinga.swoogo.com/digital-assets/6342807"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/13234126/905735A6-57D3-4874-9AA1-75D037842DB3-1-12.gif" alt="" class="wp-image-646853" /></a></figure>
Ro cited Elsa Madrolle of VerifyVASP, who recently posted on LinkedIn that the European Banking Authority (EBA) proposed a "tolerance period of six months during which full travel rule functionality mishaps will be tolerated." However, according to Ro, the terms of this transition remain unclear, as some providers might be permitted to implement the rule gradually, while others may not receive the same leeway.
Madrolle's post further reveals a lack of consensus among regulators, particularly concerning whether CASPs will be allowed "grandfather" status or need immediate compliance by the end-of-year deadline. As Ro explained, interpretations of MiCA's provisions could vary widely, leaving questions about the enforcement scope.
<h1 class="wp-block-heading">Compliance and Potential Enforcement Challenges</h1>
Ro stressed that meeting MiCA's compliance standards will not be straightforward for many operators. "The practicality of implementation is often less straightforward than practitioners would like as specific details or concepts like being ‘grandfathered or not' are up for interpretation," she said. 
These challenges raise questions about how enforcement might unfold, especially if crypto exchanges and CASPs are labeled "non-compliant" for failing to meet MiCA's demands on time. As Europe's digital asset market adjusts to these incoming regulations, Ro's remarks suggest that the MiCA framework could reshape the landscape for well-established and newer entrants in the industry. 
For more of Madrolle's analysis on the topic, her LinkedIn post can be viewed here. Ro is expected to delve further into these issues at the <a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets</a> event as the industry prepares for upcoming regulatory developments in the European market.
<hr class="wp-block-separator has-alpha-channel-opacity" />
As the digital asset market continues to mature, the convergence of regulatory shifts, M&amp;A activities, and adoption trends will define the future of this dynamic field. <a href="https://www.benzinga.com/digital-assets" target="_blank" rel="noreferrer noopener">Benzinga's Future of Digital Assets</a> event in New York City on Nov. 19 will provide industry leaders and investors with a platform to explore these developments further, offering insights into the evolving regulatory environment and the latest market dynamics.
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Global

Interview

As MiCA Compliance Deadline Approaches, Will European Crypto Exchanges Face Enforcement Risks?

Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) has unveiled its upcoming additions to Xbox Game Pass for the second half of November, featuring high-profile launches and exciting<a href="https://www.benzinga.com/general/gaming"> indie gems. </a>
Subscribers can look forward to a mix of blockbuster games, indie adventures, and in-game rewards, though a handful of titles will soon leave the service.
<h3 class="wp-block-heading">New Additions To Xbox Game Pass:</h3>
Here's a breakdown of the new titles arriving on Xbox Game Pass in late November, as <a href="https://news.xbox.com/en-us/2024/11/19/xbox-game-pass-november-2024-wave-2/">detailed</a> in an Xbox blog post:
See Also: <a href="https://www.benzinga.com/general/gaming/24/11/42013601/phil-spencer-responds-to-this-is-an-xbox-criticism-were-in-the-middle-of-a-transition">Phil Spencer Responds To &#8216;This Is An Xbox&#8217; Criticism: &#8216;We&#8217;re In The Middle Of A Transition&#8217;</a>
<ul>
<li>Microsoft Flight Simulator 2024 (Cloud, PC, and Xbox Series X&#x7C;S) – Nov. 19: The latest iteration of this iconic series pushes realism and immersive gameplay to new heights. Available with Game Pass Ultimate and PC Game Pass.</li>
<li>Stalker 2: Heart of Chornobyl (Cloud, PC, and Xbox Series X&#x7C;S) – Nov. 20: The long-anticipated survival-horror shooter from GSC Game World finally launches. Ultimate and PC Game Pass subscribers can dive into this atmospheric journey.</li>
<li>Little Kitty, Big City (Console) – Nov. 20: A whimsical adventure now available to standard Game Pass subscribers.</li>
<li>PlateUp! (Console) – Nov. 20: A chaotic cooking simulator arrives for standard Game Pass users, blending fun and strategy.</li>
<li>Nine Sols (Cloud, PC, and Xbox Series X&#x7C;S) – Nov. 26: An artistic action-platformer with Sekiro-inspired combat. Exclusive to Ultimate and PC Game Pass.</li>
<li>Aliens: Dark Descent (Cloud, PC, and Xbox Series X&#x7C;S) – Nov. 27: Last year's well-received tactical title, based on the Aliens universe, comes to Ultimate and PC Game Pass.</li>
</ul>
<h3 class="wp-block-heading">Exclusive Rewards For Genshin Impact Players</h3>
With Genshin Impact launching on Xbox on Nov. 20, Game Pass Ultimate subscribers will receive an exclusive bundle of in-game rewards to kickstart their journey in the Hoyoverse RPG. Rewards include Intertwined Fates, Mora, and other resources.
<h3 class="wp-block-heading">Departures From Game Pass</h3>
On Nov. 30, several titles will leave the Xbox Game Pass catalog, including fan favorites like Conan Exiles and Remnant: From the Ashes.<a href="https://www.benzinga.com/24/11/42044705/this-six-games-are-leaving-xbox-game-pass-by-months-end"> Here's</a> the full list of departing games.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/41985800/gta-5-joins-novembers-playstation-plus-lineup-with-other-fan-favorites">GTA 5 Joins November&#8217;s PlayStation Plus Lineup With Other Fan-Favorites</a></li>
</ul>
Image: Shutterstock

MSFT

Xbox Game Pass Brings Big Titles In Late November, Including Stalker, Microsoft Flight Simulator 2024

Cardiol Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDL#NASDAQ">CRDL</a>), a clinical-stage life sciences company, reported results from its Phase II open-label MAvERIC-Pilot study of CardiolRx, a cannabidiol-based therapy for treating symptomatic recurrent pericarditis. Cannabidiol (CBD) is a non-psychoactive compound found in the cannabis plant.
The study, presented at the American Heart Association Scientific Sessions 2024, showed sustained reductions in pericarditis pain and inflammation over 26 weeks.
&#8220;The data reported today show that patients enrolled in MAvERIC-Pilot, despite the severity of their disease, experienced clinically relevant and rapid reductions in both their pericarditis pain and C-reactive protein levels that were maintained throughout the study," stated Dr. S. Allen Luis, co-director of the Pericardial Diseases Clinic and associate professor of Medicine in the Department of Cardiovascular Medicine at the Mayo Clinic. "In addition, results demonstrated a substantial reduction in pericarditis episodes per year as compared to the patients&#8217; historical event rate prior to the study. Importantly, treatment was shown to be safe and well tolerated in a population who presented with significant disease burden. I look forward to further investigation in the upcoming Phase II/III and Phase III clinical trials.&#8221;
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40352070/cannabis-and-heart-attack-paradox-new-study-reveals-better-outcomes-for-weed-users">Cannabis And Heart Attack Paradox: New Study Reveals Better Outcomes For Weed Users</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Study Key Takeaways</h2>
The trial enrolled 27 participants (67% female, average age 53) at eight U.S. clinical sites. Patients, with a baseline history of 5.8 episodes per year and significant disease burden, received CardiolRx in addition to existing therapies before transitioning to monotherapy during the study's extension period.
<ul>
<li>Pericardial pain was reduced from 5.8 at baseline to 1.5 at week 26.</li>
<li>Just five days following initiation of CardiolRx, near resolution of pain was observed.</li>
<li>Improvements in inflammation were noted with C-reactive protein (CRP) levels normalizing in 80% of patients by week eight, with sustained improvements throughout the study</li>
<li>At week 8, 93% (25/27) of patients reported a pain score reduction.</li>
<li>CardiolRx was well tolerated, with no significant adverse events reported and a 95% compliance rate.</li>
</ul>
&#8220;The compelling results from MAvERIC-Pilot showed that CardiolRx resulted in marked and rapid reductions in pericarditis pain and inflammation in patients with a high degree of disease burden as well as a striking decrease in pericarditis episodes per year," stated David Elsley, president and CEO of Cardiol Therapeutics. "The notable impact of CardiolRx on these important clinical endpoints demonstrates its potential to offer a more accessible and non-immunosuppressive therapeutic option for tens of thousands of pericarditis patients.&#8221;
Elsley added that these results support advancing the MAVERIC program, which includes the upcoming Phase II/III MAVERIC-1 and Phase III MAVERIC-3 trials.
Cardiol focuses on developing anti-inflammatory and anti-fibrotic therapies for heart diseases. Its lead drug, CardiolRx, leverages cannabidiol's ability to inhibit inflammasome pathways, with applications in pericarditis, myocarditis, and heart failure. The company holds Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis.
<h2 class="wp-block-heading">Price Action</h2>
Cardiol Therapeutics shares closed Monday's market session 1.65% lower at $1.79 per share.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39846088/study-shows-cbd-could-protect-skin-from-sun-damage-by-exposing-participants-to-3x-uv-radiation">Study Shows CBD Could Protect Skin From Sun Damage By Exposing Participants To 3X UV Radiation</a></li>
</ul>
Photo: Courtesy of <a href="https://www.shutterstock.com/g/ARMMY+PICCA">ARMMY PICCA</a> via Shutterstock

Cannabis

CRDL

CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study

NVDA

Nvidia shares are trading higher after multiple analysts raised their price targets on the stock. The company will report Q3 earnings tomorrow.

<a href="https://truthsocial.com/@realDonaldTrump/posts/113511235978420631" title="https://truthsocial.com/@realDonaldTrump/posts/113511235978420631">https://truthsocial.com/@realDonaldTrump/posts/113511235978420631</a>

Macro Economic Events

Politics

Economics

General

President Donald Trump Posts On Truth Social "I Am Thrilled To Announce That Howard Lutnick, Chairman & CEO Of Cantor Fitzgerald, Will Join My Administration As The U.S. Secretary Of Commerce..."

BofA Securities analyst Andrew Obin reiterated the Buy rating on Vertiv Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>), <a target="_blank" href="https://www.benzinga.com/quote/VRT/analyst-ratings" rel="noreferrer noopener">with a price forecast of $150.</a>
Obin writes that, management has revised its organic revenue growth forecast to a 12%-14% CAGR from 2024 to 2029, up from a previous range of 8%-11%.
This compares to BofA and consensus estimates of a 14% CAGR from 2024-2027.
The analyst attributes the revision to potential industry-wide constraints, such as electricity availability and skilled labor shortages.
Vertiv&#8217;s capital expenditure is projected to increase, with capex rising to approximately 3.0% of revenue in 2025, up from 2.6% in 2024, indicating a continued acceleration of capacity expansions.
Also Read<a target="_blank" href="https://www.benzinga.com/news/events/24/11/42069387/grant-cardone-calls-himself-a-coward-investor-puts-his-money-in-real-assets" rel="noreferrer noopener">: Grant Cardone Calls Himself A &#8216;Coward Investor,&#8217; Puts His Money In &#8216;Real Assets&#8217;</a>
As of 3Q24, Vertiv&#8217;s gross equipment assets grew by 25% year-over-year, the analyst writes.
Management also guided for an adjusted operating margin of 25+% by 2029 (or sooner), an improvement from the previous target of 20+% by 2028.
This enhanced margin outlook is despite an increase in R&amp;D and capacity investment, which is now expected to reach $150-200 million per year, up from the previous $75-125 million range, Obin adds.
The analyst raised the 2025 adj. EPS estimate by $0.10 to $3.60 (+33% year over year), driven largely by faster revenue growth.
Obin raised the 2026 adj. EPS estimate by $0.15 to $4.40 (+22% year over year).
The analyst also raised the dividend forecast to reflect the 50% increase to $0.15/share annualized rate in conjunction with the Investor Day.
Price Action: VRT shares are trading higher by 10.9% to $136.49&nbsp;at last check Tuesday.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42046709/raoul-pal-bullish-on-solana-and-memes-dogecoin-does-nothing-does-nothing-and-then-explodes" target="_blank" rel="noreferrer noopener">Raoul Pal Bullish On Solana And Memes: &#8216;Dogecoin Does Nothing, Does Nothing And Then Explodes&#8217;</a></li>
</ul>

Analyst Color

Equities

Price Target

Reiteration

Markets

Analyst Ratings

Movers

Trading Ideas

Vertiv's Earnings Estimates Raised By Analyst Amid Improved Margin Outlook

Investors seem to be throwing in the towel on China very quickly. However, their market has not really fallen back as much as it seems over the past few weeks.
Also, we have to think about what it will mean to President Xi &#8216;s standing on the global stage if he does not come through with a bigger stimulus bazooka blast at some point over the next six months.
One of the narratives on Wall Street that I think is off base is the belief that China &#8216;s economy and markets are headed into the toilet, and that this bearish theme is going to accelerate in the weeks and months ahead. I admit that I&#8217;m not sure what is going to happen over the next few weeks, but I do believe that things will improve through much of 2025, beginning no later than early in the new year.
No, this does not mean that the efforts by Chinese authorities will fix the country&#8217;s long-term structural problems, but I do think their efforts will help improve the situation in China over the intermediate-term.
There is little question that Chinese authorities have not provided the kind of "bazooka blast" of stimulus as quickly as many people thought they would in September, when they first implied that they&#8217;d do whatever it takes to stimulate their economy. However, this does not mean that they won&#8217;t shoot that bazooka in the future. The Chinese, led by President X, have put a lot of political capital on the line with their announcements in September, so if they don&#8217;t follow-through, it&#8217;s going to make them look very weak on the global stage (especially with President Trump about to become President once again).
I am not an expert on geopolitical issues, but I don&#8217;t see President XI allowing the promises he and his government made back in September to be left flapping in the breeze in 2025.
I also want to put things into perspective when it comes to their stock market. After the massive 30% rally that came in just six days, the CSI 300 index is down "only" 6% from its closing high in early October.
Yes, it&#8217;s down more than 10% from its intraday high on October 8th, but the parabolic move that came at the end of that rally lasted for only a few minutes that day, before closing 5% below its intraday highs. In other words, on a closing basis, the CSI 300 has not fallen in a dramatic way and it still stands 25% above its September lows!
As we move forward, I&#8217;ll be watching the late-October lows of 3,800 for the CSI 300. If it can break above its October closing high of 4,256 and thus follow up that "higher-low" with a "higher-high," it&#8217;s going to be very bullish for China&#8217;s stock market on a technical basis. If (I repeat, IF) it is able to break above its 2024 highs at any point in the coming months, it will be extremely bullish for Chinese stocks!
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="524" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19141303/China-CSI-1024x524.png" alt="" class="wp-image-655813" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19141303/China-CSI-1024x524.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19141303/China-CSI-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19141303/China-CSI-768x393.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19141303/China-CSI.png 1179w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
One thing that does concern me, however, is the action in South Korea &#8216;s KOSPI index. As I mentioned last week, the KOSPI index has been hit hard since the US election after already experiencing a rough four months. It is now down over 16%, and it has broken below its summer lows. It is now very close to testing its trend-line going all the way back to the October 2022 lows. So, a break below that level would be quite bearish on a technical basis.
That said, the KOSPI is getting oversold, so it could bounce soon. However, if it breaks below that line in any meaningful way, either now, or after a short-term bounce, it will not be good at all. Since South Korea is such a big exporter, especially to China, a further decline in the KOSPI would not be a good sign at all for China &#8216;s economy.
In other words, I do admit that the problems in China could be too difficult for the authorities to control going forward. Thus, I&#8217;ll be watching the KOSPI index for clues on this front.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="515" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19141316/South-Korea-KOSPI-1024x515.png" alt="" class="wp-image-655815" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19141316/South-Korea-KOSPI-1024x515.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19141316/South-Korea-KOSPI-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19141316/South-Korea-KOSPI-768x386.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19141316/South-Korea-KOSPI.png 1154w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
 This week, you can join my Inner Circle for just $199 (regularly $3,000) and get immediate access to the same strategies and trade setups that have helped my members achieve 100%+ gains. <a href="https://www.benzinga.com/premium/ideas/matt-199-offer/?utm_source=WebRD-1119">Click Here to Join!</a>
Image via Shutterstock

Opinion

How You'll Know That Chinese Stocks Are About To Take Off

Trulieve Cannabis Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>, CSE:<a class="ticker" href="https://www.benzinga.com/stock/TRUL#CSE">TRUL</a>) executives recently purchased 26,000 shares, signaling potential confidence in the company's future. Between November 8 and 13, COO Marie Zhang, CPO Kyle Landrum, and CLO Eric Powers increased their holdings, according to a report by Beacon Securities. 
Zhang made the largest move, acquiring 21,300 shares at an average price of $7.19, adding $153,147 of an estimated total of around $186.000. What does this mean for investors? Is the stock undervalued?
<h3 class="wp-block-heading">Stock Decline</h3>
Trulieve's stock has dropped sharply in recent weeks, trading at around $6.34 after peaking at $14 in mid-October. The decline follows two major setbacks: the failure of Florida's cannabis legalization ballot and heightened political uncertainty tied to Donald Trump's election victory.
These setbacks created an election gapt hat the stock has yet to close.
There&#8217;s a reason why those events had a significant impact on the company. <a href="https://www.benzinga.com/topic/florida-cannabis">Florida</a> is the company's largest market, and the <a href="https://www.benzinga.com/markets/cannabis/24/11/41780079/floridas-cannabis-initiative-defeated-trulieve-ceo-kim-rivers-nfls-ricky-williams-and-others-res">ballot's failure</a> denied an opportunity to double the size of the state's legal cannabis market. A Trump presidency also <a href="https://www.benzinga.com/general/market-summary/24/11/42049450/can-trumps-return-save-the-cannabis-sector-debt-mounts-as-giants-face-post-election-reckoning">raises concerns</a> about the future of federal cannabis reform, further complicating Trulieve's growth outlook.
The ballot's defeat was particularly damaging. If approved, it would have allowed Trulieve to expand its 156 Florida stores into the recreational market, dramatically boosting revenue potential.
Adding to these challenges, Trulieve's third-quarter 2024 earnings showed <a href="https://www.benzinga.com/markets/cannabis/24/11/41743807/trulieves-q3-revenue-up-slightly-year-over-year-net-loss-grows-amid-48m-in-cannabis-legalization">mixed results</a>. The company reported $284 million in revenue, a modest 3% increase from the previous year, with a strong gross margin of 61% and adjusted EBITDA of $96 million (up 24% year-over-year). However, a $60 million net loss, significantly higher than the $25.4 million loss in Q3 2023 highlighted the financial strain of $48 million in non-recurring expenses tied to the Florida ballot campaign.
Read Also: <a href="https://www.benzinga.com/general/market-summary/24/11/42049450/can-trumps-return-save-the-cannabis-sector-debt-mounts-as-giants-face-post-election-reckoning">Can Trump&#8217;s Return Save The Cannabis Sector? Debt Mounts As Giants Face Post-Election Reckoning</a>
Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.
<h3 class="wp-block-heading">Is Trulieve Undervalued?</h3>
<a href="https://www.benzinga.com/markets/cannabis/22/05/27419808/trulieve-executives-buying-their-company-shares-heres-what-we-know">Insider stock purchases</a> often indicate that management views the stock as undervalued. These moves could also be intended to restore investor confidence after a significant drop. However, determining undervaluation is complex and subjective, often requiring a mix of financial analyses and market sentiment.
From a technical perspective, Trulieve appears oversold, with an RSI of 31.94, suggesting the possibility of a rebound. Key resistance levels are $9.58 (SMA) and $14 (the October high), while support hovers at $6.00, with a critical floor near $3.71 (lower Bollinger Band). Recent high volumes during the selloff suggest heavy selling pressure, but the current lower volumes indicate stabilization. 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="630" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19123625/Captura-de-pantalla-2024-11-19-a-las-14.36.18-1024x630.png" alt="" class="wp-image-655536" style="width:613px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19123625/Captura-de-pantalla-2024-11-19-a-las-14.36.18-1024x630.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19123625/Captura-de-pantalla-2024-11-19-a-las-14.36.18-300x185.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19123625/Captura-de-pantalla-2024-11-19-a-las-14.36.18-768x473.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19123625/Captura-de-pantalla-2024-11-19-a-las-14.36.18.png 1071w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Chart <a href="https://pro.benzinga.com/dashboard">created using Benzinga Pro</a>
At a glance, it seems the market has not bought yet on the promising future this cannabis company has to offer, with or without legal recreational cannabis in Florida. But, with small-cap cannabis stocks prone to volatility, this is a situation investors should monitor closely.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/11/41743807/trulieves-q3-revenue-up-slightly-year-over-year-net-loss-grows-amid-48m-in-cannabis-legalization">Trulieve&#8217;s Q3 Revenue Up Slightly Year-Over-Year, Net Loss Grows Amid $48M In Cannabis Legalization Support</a></li>
</ul>
Cover: AI generated image

Buybacks

CSE:TRUL

TCNNF

Trulieve Cannabis Execs Buy 26K Company Shares: What Does This Mean For Investors?

<a href="https://www.benzinga.com/digital-assets/livestream" title="https://www.benzinga.com/digital-assets/livestream">https://www.benzinga.com/digital-assets/livestream</a>

Benzinga's Future Of Digital Assets Panel 'The Promises and Complexity of Internet Breakthroughs' Begins

While artificial intelligence (AI) has <a href="https://www.benzinga.com/top-stories/24/06/39383798/the-ai-big-10-10-ai-stocks-now-comprise-28-of-s-p-500-up-from-14-in-2023">excited financial markets</a> in recent years, its ultimate use is still unclear, especially in fields such as fintech. 
Some experts argue that AI can be a personal assistant to investors. Others expect it will be a successful market participant itself.
At <a href="https://www.benzinga.com/fintech-awards?__hstc=28787939.10807d109b89cb9ef22407afd6bab75f.1732029302927.1732029302927.1732032548549.2&amp;__hssc=28787939.2.1732032548549&amp;__hsfp=2110343318">Benzinga&#8217;s Fintech Deal Day</a> in New York City, experts gathered Tuesday to discuss the future of AI as part of the panel &#8220;The Latest Catchphrases Disrupting Financial Services.&#8221;
Jerome Favresse, the Chief Operating Officer of Trading Central, says AI presents an opportunity of &#8220;personalization at scale,&#8221; allowing novice and advanced investors to utilize it to answer questions at scale. He does not expect AI to be predictive but it can be utilized to garner predictive analytics.
Eugene Sorenson, the head of ChartIQ at S&amp;P Global, agreed that AI will make market participants more efficient, but it will not fundamentally change the financial markets. He emphasized that markets express the collective opinion of all of its participants and new market actors will not necessarily change this.
 Jan Szilagyi, the Founder and CEO of Reflexivity, begged to differ.
&#8220;There is this prevailing view that it&#8217;s very easy to subscribe to that AI is in, effect, a very friendly assistant. I think that&#8217;s a temporary phase—eventually, AI will outgrow that phase just like you start as an apprentice and then become a master of something,&#8221; the former asset manager and algorithmic trader said.
Szilagyi says not everyone will be able to profit off AI&#8217;s use. But systems will evolve to perform better trades than human will.
Big Data: All of the panel participants agreed that artificial intelligence will revolutionize the use of data.
Leslie Kanthan, the CEO of TurinTech AI, emphasized the future capabilities of AI in distilling data and expanding what could qualify as data. While analysts have traditionally viewed data as purely financial, Kanthan posited that the understanding of data could be expanded to legal contracts and documents with the help of AI. He also noted the potential of AI to optimize coding and reduce costs and consumption.
Favresse agreed, highlighting the ability of AI to &#8220;cut through noise and find what&#8217;s meaningful.&#8221;
Now Read:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/technicals/24/11/42063336/nvidia-blackwell-chips-face-heat-will-q3-earnings-cool-investor-concerns">Nvidia&#8217;s Blackwell Chips Overheat: Will Q3 Earnings Cool Investor Concerns?</a>&#8216;</li>
</ul>
Image: Midjourney

Fintech news covering the emerging Financial Technology services sector

Fintech

Tech

Will AI Become An Assistant Or A Master? Experts Beg To Differ At Benzinga Fintech Conference

<a href="https://x.com/saylor/status/1858945523258159169" title="https://x.com/saylor/status/1858945523258159169">https://x.com/saylor/status/1858945523258159169</a>

MSTR

Shares Of Rumble See Volume To The Upside; MicroStrategy Executive Chairman Michael Saylor Replying To Rumble CEO Post About Co. Adding Bitcoin To Its Balance Sheet, Says, "Yes. I would be happy to discuss why & how with you."

Investors with a lot of money to spend have taken a bullish stance on GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GEO, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 32 uncommon options trades for GEO Group.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 28%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $95,098, and 30 are calls, for a total amount of $3,871,205.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $3.0 to $30.5 for GEO Group during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for GEO Group's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of GEO Group's whale trades within a strike price range from $3.0 to $30.5 in the last 30 days. 
<h3>GEO Group Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732043745_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GEO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$4.0</td>
<td>$3.6</td>
<td>$3.8</td>
<td>$30.00</td>
<td>$1.3M</td>
<td>659</td>
<td>6.9K</td>
</tr>
<tr>
<td>GEO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$25.3</td>
<td>$24.3</td>
<td>$25.3</td>
<td>$3.00</td>
<td>$371.9K</td>
<td>5</td>
<td>202</td>
</tr>
<tr>
<td>GEO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$7.0</td>
<td>$6.9</td>
<td>$7.0</td>
<td>$22.00</td>
<td>$336.7K</td>
<td>29.9K</td>
<td>523</td>
</tr>
<tr>
<td>GEO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$6.6</td>
<td>$6.5</td>
<td>$6.6</td>
<td>$22.00</td>
<td>$161.7K</td>
<td>2.6K</td>
<td>254</td>
</tr>
<tr>
<td>GEO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.1</td>
<td>$3.9</td>
<td>$3.9</td>
<td>$30.00</td>
<td>$117.3K</td>
<td>659</td>
<td>539</td>
</tr>
</tbody>
</table>

<h3>About GEO Group</h3>
The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services.
Following our analysis of the options activities associated with GEO Group, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of GEO Group</h3>
<ul>
<li>Currently trading with a volume of 2,539,496, the GEO's price is up by 6.71%, now at $28.15. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 86 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for GEO Group, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Looking At GEO Group's Recent Unusual Options Activity

Investors with a lot of money to spend have taken a bearish stance on Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CLS, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 13 options trades for Celestica.
This isn't normal.
The overall sentiment of these big-money traders is split between 46% bullish and 53%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $29,000, and 12, calls, for a total amount of $3,259,794.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $27.5 to $100.0 for Celestica over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Celestica stands at 542.89, with a total volume reaching 7,498.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Celestica, situated within the strike price corridor from $27.5 to $100.0, throughout the last 30 days.
<h3>Celestica 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732043739_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$22.3</td>
<td>$21.6</td>
<td>$22.1</td>
<td>$85.00</td>
<td>$2.2M</td>
<td>3.0K</td>
<td>1.0K</td>
</tr>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$23.0</td>
<td>$22.3</td>
<td>$22.4</td>
<td>$62.50</td>
<td>$257.6K</td>
<td>453</td>
<td>130</td>
</tr>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$57.0</td>
<td>$54.8</td>
<td>$57.0</td>
<td>$27.50</td>
<td>$171.0K</td>
<td>122</td>
<td>30</td>
</tr>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.15</td>
<td>$2.05</td>
<td>$2.05</td>
<td>$95.00</td>
<td>$153.7K</td>
<td>304</td>
<td>762</td>
</tr>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$15.9</td>
<td>$15.3</td>
<td>$15.3</td>
<td>$80.00</td>
<td>$87.2K</td>
<td>37</td>
<td>583</td>
</tr>
</tbody>
</table>

<h3>About Celestica</h3>
Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity &amp; Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity &amp; Cloud Solutions segment.
In light of the recent options history for Celestica, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Celestica Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 1,051,582, the CLS's price is up by 3.49%, now at $86.9. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 69 days.</li>
</ul>
<h3>Expert Opinions on Celestica</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $75.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Barclays has revised its rating downward to Overweight, adjusting the price target to $91. 
&#x2A; An analyst from BMO Capital has decided to maintain their Outperform rating on Celestica, which currently sits at a price target of $72. 
&#x2A; An analyst from Stifel persists with their Buy rating on Celestica, maintaining a target price of $70. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Celestica with a target price of $75. 
&#x2A; An analyst from TD Cowen persists with their Buy rating on Celestica, maintaining a target price of $70. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Celestica options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Spotlight on Celestica: Analyzing the Surge in Options Activity

Deep-pocketed investors have adopted a bullish approach towards Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CAT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Caterpillar. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 44% leaning bullish and 33% bearish. Among these notable options, 5 are puts, totaling $225,945, and 4 are calls, amounting to $165,460.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $230.0 to $420.0 for Caterpillar during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Caterpillar options trades today is 639.5 with a total volume of 453.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Caterpillar's big money trades within a strike price range of $230.0 to $420.0 over the last 30 days.
<h3>Caterpillar Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732043734_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$154.75</td>
<td>$153.7</td>
<td>$154.75</td>
<td>$230.00</td>
<td>$77.3K</td>
<td>115</td>
<td align="right">6</td>
</tr>
<tr>
<td>CAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$14.85</td>
<td>$14.15</td>
<td>$14.85</td>
<td>$350.00</td>
<td>$74.2K</td>
<td>145</td>
<td align="right">50</td>
</tr>
<tr>
<td>CAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$26.4</td>
<td>$24.8</td>
<td>$25.45</td>
<td>$400.00</td>
<td>$50.9K</td>
<td>784</td>
<td align="right">50</td>
</tr>
<tr>
<td>CAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/29/24</td>
<td>$18.55</td>
<td>$17.9</td>
<td>$18.23</td>
<td>$400.00</td>
<td>$36.4K</td>
<td>66</td>
<td align="right">1</td>
</tr>
<tr>
<td>CAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$17.25</td>
<td>$17.0</td>
<td>$17.0</td>
<td>$390.00</td>
<td>$35.7K</td>
<td>1.1K</td>
<td align="right">90</td>
</tr>
</tbody>
</table>

<h3>About Caterpillar</h3>
Caterpillar is the top manufacturer of heavy equipment, power solutions, and locomotives. It is currently the world's largest manufacturer of heavy equipment. The company is divided into four reportable segments: construction industries, resource industries, energy and transportation, and Cat Financial. Its products are available through a dealer network that covers the globe with about 2,700 branches maintained by 160 dealers. Cat Financial provides retail financing for machinery and engines to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Caterpillar product sales.
Following our analysis of the options activities associated with Caterpillar, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Caterpillar</h3>
<ul>
<li>With a volume of 822,171, the price of CAT is down -0.4% at $382.94. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 76 days.</li>
</ul>
<h3>What The Experts Say On Caterpillar</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $348.75.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Evercore ISI Group downgraded its rating to Underperform, setting a price target of $365. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on Caterpillar, which currently sits at a price target of $435. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Sell rating for Caterpillar, targeting a price of $295. 
&#x2A; An analyst from Baird has decided to maintain their Underperform rating on Caterpillar, which currently sits at a price target of $300. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Caterpillar, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

What the Options Market Tells Us About Caterpillar

Symbotic Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) shares are soaring Tuesday after <a href="https://www.benzinga.com/24/11/42058176/why-symbotic-shares-are-trading-higher-by-over-28-here-are-20-stocks-moving-premarket">the company reported blowout numbers</a> for the fourth quater. The Street was looking for revenues of $470.27 million. The company reported $576.76 million. It also reported earnings of five cents, <a href="https://www.benzinga.com/news/earnings/24/11/42049125/symbotic-stock-rallies-after-strong-q4-results-details">which was ahead of estimates of three cents</a>.
Despite this, some are taking advantage of this move higher to exit their positions. This is why our team of expert traders has made it the Stock of the Day.
It is important for traders and investors to understand the fundamentals of the stocks they are trading. It is also important for them to understand the technicals.
Symbotic's gross profit margin increased from 15% to 18.8%; net income was $28,073,000. A year ago, the company reported a loss of $45,415,000.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/upgrades/24/11/42069455/this-biontech-analyst-turns-bullish-here-are-top-5-upgrades-for-tuesday">This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday</a>
Regardless of the quarter&#8217;s outstanding results, the stock may have run into a ceiling. It may even be about to reverse and head lower.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="533" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19140735/Symboitc1-1024x533.png" alt="" class="wp-image-655803" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19140735/Symboitc1-1024x533.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19140735/Symboitc1-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19140735/Symboitc1-768x400.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19140735/Symboitc1-1536x799.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19140735/Symboitc1.png 1582w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
As you can see on the chart, the shares peaked in the middle of July around the $41 level. Now some investors and traders who bought shares then are taking advantage of the move higher. They had been looking at losses since the price moved lower at the end of July.
Now they have a chance to sell their shares at the same price they paid for them. This will allow them to get out of their positions at breakeven.
So, they place sell orders at their buying price. This large concentration of sell orders has created resistance at the same level that had previously been resistance.
Some of these sellers may become concerned that others will be willing to sell at lower prices than they are. They know the traders and investors who wish to buy will go to whoever is willing to sell at the lowest price.
As a result, they reduce the prices they are offering their shares. This could result in a snowball effect that pushes the stock lower as other concerned sellers see this and do the same thing.
Some traders focus on fundamentals. Some traders focus on technicals. The best traders focus on both.
Read Next: • <a href="https://www.benzinga.com/news/global/24/11/42064198/putin-revises-nuclear-doctrine-for-broader-strikes-after-us-backed-ukrainian-attack-markets-drop-bonds-gain">Putin Revises Nuclear Doctrine For Broader Strikes After US-Backed Ukrainian Attack: Markets Drop, Bonds Gain</a>
Photo: Shutterstock

Technicals

Topics

Stock Of The Day: Symbotic Soars — But For How Long?

A couple of analysts initiated coverage on Septerna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>), which <a target="_blank" href="https://www.benzinga.com//node/41637739" rel="noreferrer noopener">debuted on NASDAQ last month.</a>
Cantor analyst Josh Schimmer initiated coverage at an <a target="_blank" href="https://www.benzinga.com/quote/sepn/analyst-ratings" rel="noreferrer noopener">Overweight rating with a price target of $50.</a>
The analyst says that SEPN&#8217;s advanced platform accelerates the discovery of novel GPCR-targeting therapeutics, addressing a significant unmet need.
Leveraging CryoEM technology, SEPN reconstitutes GPCRs in lipid bilayers, enabling structural analysis of targets previously deemed &#8220;undruggable.&#8221; This unlocks potential in a $125 billion market where over 50% of GPCR targets remain untapped, adds the analyst.
Schimmer writes that SEPN&#8217;s lead asset, SEP-786, targets hypoparathyroidism (hypoPTH), a severe endocrine disorder affecting approximately 70,000 U.S. patients.
That analyst anticipates Phase 1 single-ascending and multiple-ascending dose data by mid-2025, offering potential advancements in chronic therapy for low parathyroid hormone and serum calcium levels.
This will be a key de-risking milestone, as early hypoparathyroidism trials often predict late-stage success, and it will also validate SEPN&#8217;s innovative GPCR-targeting platform, adds the analyst.
Additionally, the analyst assumes a $250 million platform value, reflecting SEPN&#8217;s differentiated GPCR capabilities and the potential of its disclosed and undisclosed pipeline programs.
JP Morgan analyst Eric Joseph initiated coverage at an Overweight rating with a price target of $38.
The analyst writes that Septerna is a differentiated player in biopharma, leveraging its Native Complex Platform to enhance the development of GPCR-targeted drugs with greater control over mechanisms of action, pharmacokinetics, and selectivity.
This platform applies state-of-the-art structural biochemistry to efficiently model and design oral compounds, addressing the limitations of traditional trial-and-error methods, adds the analyst.
Joseph says the company&#8217;s pipeline strategy targets large, established indications where oral options can provide clear patient benefits.
With a potential derisking catalyst from SEP-786 for hypoparathyroidism in 2025, a cash runway through 2027, and strong business development prospects, Septerna is poised to outperform broader biopharma coverage in the mid term, adds the analyst.
Price Action: SEPN shares are down 1.32% at $23.24 at the last check Tuesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42066092" target="_blank" rel="noreferrer noopener">United Airlines Gears Up For Holiday Travel Surge To Europe: Details</a></li>
</ul>

Initiation

SEPN

Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining by around 1% on Tuesday.
The Dow traded down 0.03% to 43,374.79 while the NASDAQ rose 1.03% to 18,985.21. The S&amp;P 500 also rose, gaining, 0.49% to 5,922.41.
Check This Out: <a href="https://www.benzinga.com/24/11/42059659/this-apollo-global-management-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-tuesday">This Apollo Global Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday</a>
Leading and Lagging Sectors Information technology shares rose by 0.6% on Tuesday.
In trading on Tuesday, materials shares fell by 0.6%.
Top Headline
Medtronic Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported better-than-expected results for its second quarter and raise its outlook.
The company posted second-quarter 2025 sales of $8.40 billion, beating the consensus of $8.27 billion. The medical device maker reported adjusted EPS of $1.26, beating the consensus of $1.25.
Medtronic raised its fiscal year 2025 organic revenue growth guidance to 4.75%-5%, up from the prior 4.5%-5%. If recent foreign currency exchange rates hold, 2025 revenue growth on an adjusted basis would be 3.4%-3.9%. Medtronic expects 2025 adjusted EPS guidance to be $5.44-$5.50 versus previous guidance of $5.42-$5.50 and consensus of $5.45.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares shot up 29% to $27.84 after the company announced the appointment of BDO USA as its independent auditor and the filing of a compliance plan with Nasdaq.</li>
<li>Shares of PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) got a boost, surging 172% to $1.4600. The company announced a 1-for-4 reverse stock split.</li>
<li>Interactive Strength Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) shares were also up, gaining 30% to $3.30. The company, which makes specialty fitness equipment under the CLMBR and FORME brands, disclosed that Armah Sports Group‘s B_FIT is installing CLMBRs in three of its nine locations in Saudi Arabia.</li>
</ul>
Equities Trading DOWN
<ul>
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares dropped 12% to $1.06. NWTN received Nasdaq staff delisting determination for non-compliance with Listing Rule 5250(c)(1).</li>
<li>Shares of Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) were down 13% to $66.74 after the company announced that data from its Phase 2 study evaluating MRGPRX4 (INCB000547) in cholestatic pruritus does not support further development.</li>
<li>Codere Online Luxembourg, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDRO#NASDAQ">CDRO</a>) was down, falling 11% to $6.77 after the company received a Nasdaq delisting notice due to its public reports rule.</li>
</ul>
Commodities In commodity news, oil traded down 0.1% to $69.12 while gold traded up 0.7% at $2,632.40.
Silver traded up 0.3% to $31.305 on Tuesday, while copper rose 0.6% to $4.1435.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.45%, Germany's DAX fell 0.67% and France's CAC 40 fell 0.67%. Spain's IBEX 35 Index fell 0.74%, while London's FTSE 100 fell 0.13%.
Hourly labor costs in the Eurozone rose by 4.6% year-over-year in the third quarter compared to a revised 5% gain in the prior quarter. Annual inflation in the Eurozone rose to 2% in October from 1.7% in September.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei 225 gaining 0.51%, Hong Kong's Hang Seng Index gaining 0.44%, China's Shanghai Composite Index gaining 0.67%&nbsp; and India's BSE Sensex gaining 0.31%.
Malaysia&#8217;s trade surplus narrowed to MYR 12.0 billion in October from MYR 13.0 billion in the year-ago month.
Economics
<ul>
<li>Housing starts in the U.S. declined by 3.1% to 1.311 million in October versus a revised 1.353 million in the previous month.</li>
<li>U.S. building permits declined by 0.6% to an annual rate of 1.416 million in October.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42060404/nvidia-to-rally-more-than-19-here-are-10-top-analyst-forecasts-for-tuesday-2">Nvidia To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Earnings

Eurozone

Commodities

Intraday Update

CDRO

INCY

NWTN

PRFX

SMCI

TRNR

Gold Moves Higher; Medtronic Posts Upbeat Results

Alzamend Neuro (ALZN) has provided an update. On July 12, 2024, the Company announced a Reverse Stock Split, highlighting that this move is not an ...

Alzamend Neuro Announces Reverse Stock Split Decision

Alzamend Neuro (ALZN) just unveiled an update. Alzamend Neuro, Inc. successfully regained compliance with Nasdaq's Minimum Bid Price Requirement af...

Alzamend Neuro Meets Nasdaq Standards, Embraces Social Media

Warning: ALZN is at high risk of performing badly

Alzamend Neuro regains compliance with Nasdaq

Alzamend Neuro ( ($ALZN) ) has issued an announcement. Alzamend Neuro, a biopharmaceutical company targeting Alzheimer's and other disorders, succe...

Alzamend Neuro Regains Nasdaq Compliance After Strategic Appeal

ALZN

Press Releases

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

Alzamend Neuro Issues Letter to Stockholders

Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group's Virtual Healthcare Conference

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer's Transgenic Mice

Comments

Alzamend Neuro

Actualités

Dernières nouvelles pour Alzamend Neuro (NASDAQ:ALZN) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL